About LambdaVision

LambdaVision is designing and developing an innovative, protein-based artificial retina that utilizes a light-activated protein, bacteriorhodopsin, to restore functional sight to those who would otherwise be blind due to retinal degenerative diseases, including age-related macular degeneration (AMD) and retinitis pigmentosa (RP). No cure exists for these diseases, and currently available treatments only slow their progression. There is a significant unmet need for the development of a treatment that restores meaningful vision to those affected. Through the development of an artificial retina, LambdaVision hopes to one day help patients regain vision so that they can complete everyday tasks with independence.

LambdaVision was founded by a group of researchers led by Dr. Robert R. Birge, a distinguished professor of chemistry at UConn and a pioneer in the field of light-sensitive proteins.

old age, tourism, travel and people concept - happy senior couple over sunset background


Management Team


Nicole L. Wagner, PhD

President and Chief Executive Officer


Jordan A. Greco, PhD

Chief Scientific Officer


Robert R. Birge, PhD


Board of Directors


Nicole L. Wagner, PhD

President and Chief Executive Officer

birge headshot

Robert R. Birge, PhD



Susan Froshauer, PhD

Vice President, CURE Collaborations, LLC

Head shot June 2020

Kirk Dornbush, JD

COO and Co-Founder, Coagulant Therapeutics, Inc.

CTInnovations_CynthiaGreen-web-12 cropped

Cynthia Green

Managing Director, Investments, Connecticut Innovations


Currently, LambdaVision is partnering with Space Tango, with funding from NASA, to explore the benefits of microgravity for producing the artificial retina on the International Space Station U.S. National Laboratory (ISS) that is currently orbiting the Earth. This artificial retina is one of the first technologies being produced on the ISS that has potential for clinical use. While this therapy can be effectively developed in labs on Earth, producing the artificial retina in low-Earth orbit (LEO), improves the homogeneity of the alternating protein and polymer layers, resulting in increased stability, performance, and optical quality of the multi-layer system. These improvements could reduce the amount of materials required to produce the artificial retina, lower costs, and accelerate production time for future pre-clinical and clinical efforts.

LambdaVision, together with Space Tango, will carry out a series of flights to the ISS to evaluate and improve production processes, produce artificial retinas that can be used in pre-clinical, as well as early stage clinical testing, and define parameters for commercial-scale production. The company intends to initiate clinical trials within the next 3 years for the treatment of advanced RP, and following initial success in treating this rare disease, will expand to investigate the use of the product in AMD.

rocket wallops



At LambdaVision, we are focused on developing the first protein based artificial retina to restore meaningful vision for patients who are blind or have lost significant sight due to advanced retinal degenerative diseases, including retinitis pigmentosa (RP) and age related macular degeneration (AMD). To date, the company has secured over $10M in funding in state, local, and government research funds.

Skip to content